Media

Fusion Pharmaceuticals Announces First Patient Dosed In Phase 1 Study Of FPI-2059, A Targeted Alpha Therapy (TAT) For The Treatment Of Solid Tumors Expressing NTSR1

Fusion Pharmaceuticals Announces Fourth Quarter 2022 Financial Results And Clinical Program Updates

Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates

Targovax ASA: circRNA poster to be presented at the AACR Annual Meeting

Targovax: First patient dosed with TG01 in the USA

Oncopeptides CSO released from custody

Oncopeptides CSO investigated for violation of the Market Abuse Act

Carisma Therapeutics Closes Merger with Sesen Bio

Targovax to prioritize resources on unlocking the potential of its circRNA platform